ETOILE: Real-World Evidence of 24 Months of Ranibizumab 0.5 mg in Patients with Visual Impairment Due to Diabetic Macular Edema

References

• Klein R, Lee KE, Gangnon RE, Klein BE. The 25-year incidence of visual impairment in type 1 diabetes mellitus the Wisconsin epidemiologic study of diabetic retinopathy. Ophthalmology. 2010;117:63–70. doi:10.1016/j.ophtha.2009.06.051
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Ten-year incidence of visual loss in a diabetic population. Ophthalmology. 1994;101:1061–1070. doi:10.1016/S0161-6420(94)31217-6
   PubMed Web of Science ®Google Scholar
• Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564. doi:10.2337/dc11-1909
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter Phase II study. Diabetes Care. 2010;33:2399–2405. doi:10.2337/dc10-0493
   PubMed Web of Science ®Google Scholar
• Prünte C, Fajnkuchen F, Mahmood S, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100::787–795. doi:10.1136/bjophthalmol-2015-307249
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–625. doi:10.1016/j.ophtha.2011.01.031
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 Phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. doi:10.1016/j.ophtha.2011.12.039
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–1077 e1035. doi:10.1016/j.ophtha.2010.02.031
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009;116:2175–2181 e2171. doi:10.1016/j.ophtha.2009.04.023
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146–2151. doi:10.1016/j.ophtha.2010.08.016
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–614. doi:10.1016/j.ophtha.2010.12.033
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;121:1045–1053. doi:10.1016/j.ophtha.2013.11.041
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. Biomed Res Int. 2018;2018:8289253. doi:10.1155/2018/8289253
   PubMed Web of Science ®Google Scholar
• Creuzot-Garcher C, Massin P. Œdèmes maculaires (Société Française d’Ophtalmologie). 2016.
   Google Scholar
• Massin P, Creuzot-Garcher C, Kodjikian L, et al. Real-world outcomes after 36 months treatment with ranibizumab 0.5 mg in patients with visual impairment due to diabetic macular edema (BOREAL-DME). Ophthalmic Res. 2020. doi:10.1159/000511591
   Web of Science ®Google Scholar
• Best AL, Fajnkuchen F, Nghiem-Buffet S, et al. Treatment efficacy and compliance in patients with diabetic macular edema treated with ranibizumab in a real-life setting. J Ophthalmol. 2018;2018:4610129. doi:10.1155/2018/4610129
   PubMed Web of Science ®Google Scholar
• Hodzic-Hadzibegovic D, Sander BA, Monberg TJ, et al. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor – 2–4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines. Acta Ophthalmol. 2018;96:267–278. doi:10.1111/aos.13638
   PubMed Web of Science ®Google Scholar
• Ziemssen F, Wachtlin J, Kuehlewein L, et al. Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional, multicenter study in Germany. Diabetes Ther. 2018;9:2271–2289. doi:10.1007/s13300-018-0513-2
   PubMed Web of Science ®Google Scholar
• Hrarat L, Fajnkuchen F, Boubaya M, et al. Outcomes after a 1-year treatment with ranibizumab for diabetic macular edema in a clinical setting. Ophthalmologica. 2016;236:207–214. doi:10.1159/000453006
   Web of Science ®Google Scholar
• Epstein D, Amren U. Long-time outcome in patients treated with ranibizumab for diabetic macular edema: a 4-year study. Retina. 2018;38:183–186. doi:10.1097/IAE.0000000000001501
   Web of Science ®Google Scholar
• Egan C, Zhu H, Lee A, et al. The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. Br J Ophthalmol. 2017;101:75–80. doi:10.1136/bjophthalmol-2016-309313
   Web of Science ®Google Scholar
• Adelman R, Parnes A, Michalewska Z, et al. Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. BioMed Res Int. 2015;2015:352487.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203.
   PubMed Web of Science ®Google Scholar
• Sophie R, Lu N, Campochiaro PA. Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology. 2015;122:1395–1401. doi:10.1016/j.ophtha.2015.02.036
   PubMed Web of Science ®Google Scholar